Related Experiment Video
Updated: May 12, 2026
Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay
Published on: April 29, 2020
Great efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosis
Yan-Bo Zeng1, Shun-Hai Zhu, Hui Dong
1Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Science, Key Laboratory for Animal Parasitology of Ministry of Agriculture, Shanghai 200241.
Objective:
To identify more effective and less toxic drugs to treat animal toxoplasmosis.
Methods:
Efficacy of seven kinds of sulfonamides against Toxoplasma gondii (T. gondii) in an acute murine model was evaluated. The mice used throughout the study were randomly assigned to many groups (10 mice each), which either remained uninfected or were infected intraperitoneally with tachyzoites of T. gondii (strains RH and CN). All groups were then treated with different sulfonamides and the optimal treatment protocol was determined candidates. Sulfadiazine-sodium (SD) was used for comparison.
Results:
The optimal therapy involved gavaging mice twice per day with 250 mg/kg bw of sulfachloropyrazine-sodium (SPZ) for five days. Using this protocol, the average survival time and the time-point of 50% fatalities were prolonged significantly compared with SD treatment. Treatment with SPZ protected 40% of mice from death, and the heart and kidney tissue of these animals was parasite-free, as determined by nested-PCR. SPZ showed excellent therapeutic effects in the treatment of T. gondii in an acute murine model and is therefore a promising drug candidate for the treatment and prevention of T. gondii in animals.
Conclusions:
It can be concluded that the effective drug sulfachloropyrazine may be the new therapeutic options against animal toxoplasmosis.
Insights
Sulfachloropyrazine-sodium (SPZ) effectively treats animal toxoplasmosis, prolonging survival and clearing parasites in mice. This promising drug offers new therapeutic options for Toxoplasma gondii infections in animals.
Area of Science:
- Veterinary Medicine
- Parasitology
- Pharmacology
Background:
- Toxoplasmosis is a significant parasitic disease affecting various animal species.
- Current treatments for animal toxoplasmosis have limitations in efficacy and toxicity.
- There is a need for novel therapeutic agents to combat Toxoplasma gondii infections.
Purpose of the Study:
- To evaluate the efficacy of seven sulfonamides against Toxoplasma gondii in a murine model.
- To identify a more effective and less toxic drug for treating animal toxoplasmosis.
Main Methods:
- An acute murine model of toxoplasmosis was established using T. gondii strains RH and CN.
- Mice were treated with different sulfonamides, including sulfadiazine-sodium (SD) as a comparator.
- The optimal treatment protocol involved oral administration of sulfachloropyrazine-sodium (SPZ) at 250 mg/kg twice daily for five days.
Main Results:
- Sulfachloropyrazine-sodium (SPZ) significantly prolonged survival time and delayed mortality compared to sulfadiazine-sodium (SD).
- SPZ treatment protected 40% of infected mice from death.
- Nested-PCR analysis confirmed parasite clearance in the heart and kidney tissues of SPZ-treated survivors.
Conclusions:
- Sulfachloropyrazine-sodium (SPZ) demonstrates excellent therapeutic effects against T. gondii in an acute murine model.
- SPZ is a promising drug candidate for the treatment and prevention of toxoplasmosis in animals.
- Sulfachloropyrazine represents a potential new therapeutic option for animal toxoplasmosis.
